Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double Unit Cord Blood Transplant for Hematological Malignancies
NCT00597519Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2006
- Primary completion
- Sep 2015
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbilical cord blood in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Chronic Myeloid Leukemia (CML) and 5 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Overall Response at 1 year, Overall Survival at 1 year and 1 more. Started Mar 2006; status: completed.
02
Drugs
umbilical cord blood
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Chronic Myeloid Leukemia (CML)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00597519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597519.